TORONTO, Canada – Theralase® Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds (PDCs) for the safe and effective destruction of various cancers, bacteria and viruses, has been granted a Canadian patent for a new cancer vaccine....
Latest News
BUFFALO, NY – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy.” In this new editorial, researcher Ioannis A. Voutsadakis from Sault Area Hospital and Northern Ontario School of Medicine discusses tumor mutation burden (TMB)—a novel...
An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children’s Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del...
A clinical trial at the National Institutes of Health found that a medication, denosumab, significantly reduced abnormal bone turnover in adults with fibrous dysplasia, a rare disease marked by weak and misshapen bones. Bone turnover, a process in which old bone is continuously replaced with new bone, is unusually accelerated...
MONTREAL, Canada — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced completion of enrollment of the first six participants in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer. Sudocetaxel...
DUBLIN, Ireland — Theravance Biopharma Inc. today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The PIFR-2 study aimed to demonstrate greater improvement in lung function for YUPELRI...
ROCKVILLE, Md. — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the Independent Data Monitoring Committee (IDMC) recommended the continuation of enrollment as planned into VIRAGE, a multinational, Phase 2b, randomized,...
ROCKVILLE, Md. — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced positive topline data from the investigator sponsored Phase 1 trial conducted by collaborators at Sant Joan de Déu-Barcelona Children’s Hospital (SJD)....
For 13 consecutive years a select group of students has been solving math problems, diagramming sentences and completing science experiments — without missing a single day of school. That’s roughly 2,340 school days in a row without being marked absent. No skipping to go to a Rangers game. No fake...
BAKERSFIELD, Calif. — For those who are disabled, a wheelchair ramp can make all the difference when it comes to convenience. But for an east Bakersfield boy, that difference has been stolen. Jonathan Albiar, 12, and his parents said the thief has stolen more than just property; they’ve stolen compassion....